How long after starting Wegovy do you start seeing results?

Weeks one to four: the appetite shift arrives first

Picture the morning after your first injection. The pen is in the fridge, plain-boxed, tracked to your door by DPD the day before. You probably expected to feel different immediately. For most people, the most noticeable early change is not on the scales at all, it is at mealtimes. Portions that felt normal suddenly feel like a lot. That sense of fullness arriving sooner than usual is semaglutide doing what it is designed to do: acting on GLP-1 receptors in the brain and gut to slow gastric emptying and reduce hunger signals.

Weight loss in weeks one to four is usually modest, often one to two kilograms, and some people see less. The starting dose of 0.25 mg is calibrated to help your body adjust, not to deliver the full therapeutic effect. Side effects (nausea, loose stools, occasional fatigue) are most common during this early window and generally settle as your system adapts. Our guide to the first week on Wegovy covers what to expect in detail.

It helps to know that a quieter appetite is itself a result. Eating less without constant effort is the mechanism that leads to sustained weight loss further down the line. If you are wondering when you start to see results from Wegovy, many patients who later go on to lose significant weight describe the first few weeks as feeling like a gear change rather than a dramatic event.

Months two to four: the scales start to move more consistently

By months two to four, most people are on the 0.5 mg or 1.0 mg dose, and the weight-loss trajectory becomes steadier. Hunger is lower than it was before treatment; energy intake drops; the body begins drawing on stored fat. For many patients, this is the period when friends and family start to notice a difference, even if the person themselves is not entirely convinced yet.

Research published as part of the STEP programme found that participants lost roughly half their total trial weight during the first six months of treatment, with loss continuing (more slowly) through to the end of the 68-week study period. The rate is not linear: there are weeks when nothing seems to move, then weeks when a few kilograms shift. That pattern is normal and not a sign the medicine has stopped working.

If you are curious about when weight loss typically becomes measurable on Wegovy, the honest answer is that most people see a consistent downward trend by the end of month two, with the degree of loss varying considerably by individual.

Months four to twelve and beyond: approaching the maintenance dose

The 2.4 mg maintenance dose is usually reached around month five, and this is where the bulk of the trial results were recorded. The STEP 1 study, involving adults with obesity or overweight and at least one weight-related condition, found an average reduction of approximately 15% of body weight at 68 weeks, a figure that comes from the NEJM-published STEP 1 trial and applies to people who completed the full course alongside lifestyle changes. Individual results ranged considerably above and below that average.

In April 2026, the MHRA approved a 7.2 mg maintenance dose and a dedicated single-dose pen, with trial data reporting around 20.7% average weight loss at 72 weeks, a higher ceiling that narrows the gap with tirzepatide. The MHRA approval announcement confirms this is for adults with a BMI of 30 or above; specific dose availability is confirmed at the clinical consultation stage.

Weight loss is generally fastest in the first six months and slows as the body adjusts. This is not failure. It reflects normal physiology. Alongside the medicine, protein intake, hydration and regular movement all support how well the treatment works over time. For a fuller picture of the timeline, our page on how long results on Wegovy typically take goes into further depth, and our dedicated guide on how long before you see results on Wegovy breaks down what to expect at each stage of your dose escalation.

What affects how quickly you personally see results

Several factors shape your individual trajectory. Starting weight matters: someone with a higher BMI often sees a larger absolute loss but a similar percentage change. The presence of type 2 diabetes or other metabolic conditions can slow the rate of loss, which is why those participants in the STEP 2 trial showed slightly lower average reductions than the non-diabetic cohort in STEP 1. Sleep, stress and gut health all play a role that medication alone cannot fully override.

Consistency with doses and with lifestyle adjustments makes a real difference. The NHS England guidance on weight management injections emphasises that Wegovy is licensed for use alongside a reduced-calorie diet and increased physical activity, the medicine reduces appetite; the lifestyle work shapes what you do with that reduction.

If you are weighing up whether Wegovy is right for you, or how it compares to other licensed options, the weight-loss treatment overview covers the landscape clearly. And if cost is part of your thinking, our Wegovy pricing page explains what a private prescription actually includes, without the small print. When you are ready to speak to one of our prescribers, start your free consultation, a real clinician reviews every submission the same day it arrives.